You may remember KV Pharma running into trouble earlier this year for pricing its drug Makena (a form of progesterone already on the market) at $1500 per dose versus the $10 to $20 charged by compounding pharmacies. The resulting uproar caused them to lowe price to the bargain rate of $690 per dose. Too little too late though.
Now in a recent filing with the SEC, KV discloses that "conditions raise substantial doubt about the company's ability to continue as an ongoing concern." Karma strikes again.
Posted by Bruce Lehr Dec 14th 2011.